Search

Your search keyword '"MacDougall, Kira"' showing total 21 results
Start Over Author "MacDougall, Kira" Search Limiters Available in Library Collection
21 results on '"MacDougall, Kira"'

4. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes

Author

Wagner, Charlotte B., primary, Boucher, Ken, additional, Nedved, Adrienne, additional, Micallef, Ivana N, additional, Desai, Sanjal, additional, Hatic, Haris, additional, Goyal, Gaurav, additional, Zacholski, Erin, additional, Fegley, Amanda, additional, Sigmund, Audrey M., additional, Bond, David A., additional, Samuels, Courtney, additional, Kamdar, Manali K., additional, Ba Aqeel, Sheeba, additional, Torka, Pallawi, additional, MacDougall, Kira, additional, Borogovac, Azra, additional, Rajeeve, Sridevi, additional, Sundaram, Suchitra, additional, Fedak, Kalub, additional, Modi, Dipenkumar, additional, Travers, Elizabeth, additional, Ayyappan, Sabarish, additional, Chilakamarri, Nitin, additional, Brem, Elizabeth A., additional, Ermann, Daniel A., additional, Fitzgerald, Lindsey A., additional, Hu, Boyu, additional, Stephens, Deborah M., additional, and Shah, Harsh, additional

Published
2023
Full Text
View/download PDF

5. Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Author

Wagner, Charlotte B, primary, Ermann, Daniel A., additional, Boucher, Ken, additional, Nedved, Adrienne N., additional, Micallef, Ivana N., additional, Desai, Sanjal H, additional, Hatic, Haris, additional, Goyal, Gaurav, additional, Zacholski, Erin, additional, Fegley, Amanda, additional, Sigmund, Audrey M., additional, Bond, David A., additional, Samuels, Courtney, additional, Kamdar, Manali K., additional, Ba Aqeel, Sheeba, additional, Torka, Pallawi, additional, MacDougall, Kira, additional, Borogovac, Azra, additional, Rajeeve, Sridevi, additional, Sundaram, Suchitra, additional, Fedak, Kalub, additional, Modi, Dipenkumar, additional, Travers, Elizabeth, additional, Ayyappan, Sabarish, additional, Chilakamarri, Nitin, additional, Brem, Elizabeth A, additional, Stephens, Deborah M., additional, Hu, Boyu, additional, Fitzgerald, Lindsey A., additional, and Shah, Harsh, additional

Published
2022
Full Text
View/download PDF

6. Novel Home-Based Transfusion Model of Palliative Care in Malignant Hematology

Author

Saleem, Rabia, primary, MacDougall, Kira, additional, Hassan, Ayesha, additional, Siddiqui, Maria, additional, Khawandanah, Mohamad O., additional, Ikeguchi, Alexandra, additional, Asch, Adam S., additional, Ibrahimi, Sami, additional, Selby, George B., additional, Neelakantan, Deepika, additional, Ledford, Barbara, additional, Le, Tuan N, additional, Vesely, Sara K., additional, Day, Silas A, additional, Madison, Stefani D, additional, Struck, Bryan, additional, Armitage, John, additional, Nipp, Ryann, additional, Minor, Sarah, additional, Yuen, Carrie, additional, and Holter-Chakrabarty, Jennifer, additional

Published
2022
Full Text
View/download PDF

7. P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma

Author

Shah, Harsh, primary, Vardell, Victoria, additional, Zacholski, Erin, additional, Fegley, Amanda, additional, Fedak, Kalub, additional, Sundaram, Suchitra, additional, Rajeeve, Sridevi, additional, Goyal, Gaurav, additional, Hatic, Haris, additional, Torka, Pallawi, additional, Ba Aqeel, Sheeba, additional, Borogovac, Azra, additional, Macdougall, Kira, additional, Kothari, Shalin, additional, Kress, Anna, additional, Modi, Dipenkumar, additional, Travers, Elizabeth, additional, Chilakamarri, Nitin, additional, Brem, Elizabeth, additional, Stephens, Deborah M., additional, Hu, Boyu, additional, Fitzgerlad, Lindsey, additional, Wagner, Charlotte, additional, and Ermann, Daniel, additional

Published
2022
Full Text
View/download PDF

21. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes.

Author

Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, and Shah H

Subjects
Humans, Brentuximab Vedotin, Retrospective Studies, Neoplasm Recurrence, Local drug therapy, Stem Cell Transplantation, Chronic Disease, Treatment Outcome, Hodgkin Disease drug therapy, Hodgkin Disease pathology, Immunoconjugates adverse effects
Abstract

Sixteen cycles of Brentuximab vedotin (BV) after autologous stem cell transplant (ASCT) in high-risk relapsed/refractory classical Hodgkin lymphoma demonstrated an improved 2-year progression-free survival (PFS) over placebo. However, most patients are unable to complete all 16 cycles at full dose due to toxicity. This retrospective, multicenter study investigated the effect of cumulative maintenance BV dose on 2-year PFS. Data were collected from patients who received at least one cycle of BV maintenance after ASCT with one of the following high-risk features: primary refractory disease (PRD), extra-nodal disease (END), or relapse <12 months (RL<12) from the end of frontline therapy. Cohort 1 had patients with >75% of the planned total cumulative dose, cohort 2 with 51-75% of dose, and cohort 3 with ≤50% of dose. The primary outcome was 2-year PFS. A total of 118 patients were included. Fifty percent had PRD, 29% had RL<12, and 39% had END. Forty-four percent of patients had prior exposure to BV and 65% were in complete remission before ASCT. Only 14% of patients received the full planned BV dose. Sixty-one percent of patients discontinued maintenance early and majority of those (72%) were due to toxicity. The 2-year PFS for the entire population was 80.7%. The 2-year PFS was 89.2% for cohort 1 (n=39), 86.2% for cohort 2 (n=33), and 77.9% for cohort 3 (n=46) (P=0.70). These data are reassuring for patients who require dose reductions or discontinuation to manage toxicity.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results